Sodium Chloride, 0.9%
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
Avian InfluenzaCOVID-19InfluenzaMalariaTuberculosisWest Nile Viral Infection
Phase 1
Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults
CompletedNCT04776317
Start: 2021-03-25End: 2023-09-15Updated: 2025-05-16
A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults
CompletedNCT05755620
Start: 2023-04-05End: 2025-10-03Updated: 2025-10-31
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
Active, not recruitingNCT05945485
Start: 2023-10-16End: 2026-06-01Updated: 2026-03-20
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
Active, not recruitingNCT06735209
Start: 2025-07-23End: 2027-03-30Updated: 2026-04-03
Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults
Active, not recruitingNCT06745921
Start: 2025-02-24End: 2027-11-01Updated: 2026-04-03
Safety and Challenge Study of BCG TICE(R) Vaccination to Test Tuberculosis Immunity in Heathy Humans
WithdrawnNCT06845358
Start: 2025-11-26End: 2026-09-01Updated: 2025-12-17
A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults
Active, not recruitingNCT07019883
Start: 2025-06-12End: 2026-05-15Updated: 2026-01-30
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
RecruitingNCT07221162
Start: 2025-12-05End: 2026-11-24Target: 140Updated: 2026-04-03